Clarus Files for Chapter 11 Bankruptcy, Eyes Auction of Testosterone Therapy Jatenzo
Clarus Therapeutics (OTCPK:CRXT) filed voluntary petitions under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware and want to pursue an auction and sale of its only commercial asse
Seeking AlphaSep 6, 2022 04:31 ET
Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code
Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Hol
GlobeNewswireSep 5, 2022 22:20 ET
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results
NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and w
GlobeNewswireMay 12, 2022 09:09 ET
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis
Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of 2022 Initiation of Phase 2 clinical trial for CLAR
GlobeNewswireMay 10, 2022 09:07 ET
Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering
NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by ad
GlobeNewswireApr 27, 2022 13:45 ET
Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering
NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by ad
GlobeNewswireApr 25, 2022 09:25 ET
Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for JATENZO®
GlobeNewswireMar 30, 2022 16:17 ET
Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results
NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by
GlobeNewswireMar 29, 2022 16:19 ET
Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by ad
GlobeNewswireMar 10, 2022 09:11 ET
Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer
Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Cl
GlobeNewswireJan 18, 2022 09:06 ET
Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement
Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT)
GlobeNewswireDec 7, 2021 16:12 ET
Clarus Therapeutics Announces $15 Million Private Placement
Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT)
GlobeNewswireDec 3, 2021 09:10 ET
Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results
Third quarter 2021 revenue increased 93% year-over-year to $4.3 million Third quarter 2021 total prescription growth for JATENZO® increased 12% sequentially and 132% year-over-year Conference call and
GlobeNewswireNov 18, 2021 16:12 ET
Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results
NORTHBROOK, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by a
GlobeNewswireNov 17, 2021 16:10 ET
No Data
No Data